Lilly revenue skyrockets 48% to a massive $23B
Compartilhar
Lilly (NYSE:LLY) reported second-quarter revenue of $23 billion, up 48%, as demand for Mounjaro and Zepbound supported volume growth.
Lilly (NYSE:LLY) reported second-quarter revenue of $23 billion, up 48%, as demand for Mounjaro and Zepbound supported volume growth.
Eli Lilly (NYSE:LLY) announced positive topline Phase 3 results for its investigational triple agonist, retatrutide, from the 80-week TRIUMPH-2 and TRIUMPH-3 clinical trials.
AtaiBeckley (NASDAQ:ATAI) shares jumped about 50% after Bloomberg reported that Eli Lilly (NYSE:LLY) could acquire the psychedelic drug developer this week.
Eli Lilly (NYSE:LLY) has completed its acquisition of Centessa Pharmaceuticals, a clinical-stage company focused on orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders.
Eli Lilly (NYSE:LLY) executed a definitive agreement to acquire AtaiBeckley (NASDAQ:ATAI) for a $2.8 billion upfront equity valuation.
